These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 11513007)

  • 41. Parkinson's disease-related increase of T2*-weighted hypointensity in substantia nigra pars compacta.
    Langley J; Huddleston DE; Sedlacik J; Boelmans K; Hu XP
    Mov Disord; 2017 Mar; 32(3):441-449. PubMed ID: 28004859
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Interactions of iron, dopamine and neuromelanin pathways in brain aging and Parkinson's disease.
    Zucca FA; Segura-Aguilar J; Ferrari E; Muñoz P; Paris I; Sulzer D; Sarna T; Casella L; Zecca L
    Prog Neurobiol; 2017 Aug; 155():96-119. PubMed ID: 26455458
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Increased iron-related MRI contrast in the substantia nigra in Parkinson's disease.
    Gorell JM; Ordidge RJ; Brown GG; Deniau JC; Buderer NM; Helpern JA
    Neurology; 1995 Jun; 45(6):1138-43. PubMed ID: 7783878
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Iron transport in Parkinson's disease.
    Hirsch EC
    Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 3():S209-11. PubMed ID: 20082992
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Isradipine attenuates MPTP-induced dopamine neuron degeneration by inhibiting up-regulation of L-type calcium channels and iron accumulation in the substantia nigra of mice.
    Wang QM; Xu YY; Liu S; Ma ZG
    Oncotarget; 2017 Jul; 8(29):47284-47295. PubMed ID: 28521299
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Quantitative Analysis Versus Visual Assessment of Neuromelanin MR Imaging for the Diagnosis of Parkinson's disease.
    Reimão S; Pita Lobo P; Neutel D; Guedes LC; Coelho M; Rosa MM; Ferreira J; Abreu D; Gonçalves N; Morgado C; Nunes RG; Campos J; Ferreira JJ
    J Parkinsons Dis; 2015; 5(3):561-7. PubMed ID: 26406136
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Neuronal vulnerability in Parkinson's disease.
    Double KL
    Parkinsonism Relat Disord; 2012 Jan; 18 Suppl 1():S52-4. PubMed ID: 22166454
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Neuromelanin of the substantia nigra: a neuronal black hole with protective and toxic characteristics.
    Zecca L; Zucca FA; Wilms H; Sulzer D
    Trends Neurosci; 2003 Nov; 26(11):578-80. PubMed ID: 14585596
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Neuromelanin can protect against iron-mediated oxidative damage in system modeling iron overload of brain aging and Parkinson's disease.
    Zecca L; Casella L; Albertini A; Bellei C; Zucca FA; Engelen M; Zadlo A; Szewczyk G; Zareba M; Sarna T
    J Neurochem; 2008 Aug; 106(4):1866-75. PubMed ID: 18624918
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Reproducible detection of nigral iron deposition in 2 Parkinson's disease cohorts.
    Langley J; He N; Huddleston DE; Chen S; Yan F; Crosson B; Factor S; Hu X
    Mov Disord; 2019 Mar; 34(3):416-419. PubMed ID: 30597635
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Interaction of neuromelanin and iron in substantia nigra and other areas of human brain.
    Zecca L; Shima T; Stroppolo A; Goj C; Battiston GA; Gerbasi R; Sarna T; Swartz HM
    Neuroscience; 1996 Jul; 73(2):407-15. PubMed ID: 8783258
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Magnetic Resonance Imaging Biomarkers to Assess Substantia Nigra Damage in Idiopathic Rapid Eye Movement Sleep Behavior Disorder.
    Pyatigorskaya N; Gaurav R; Arnaldi D; Leu-Semenescu S; Yahia-Cherif L; Valabregue R; Vidailhet M; Arnulf I; Lehéricy S
    Sleep; 2017 Nov; 40(11):. PubMed ID: 28958075
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Is neuromelanin changed in Parkinson's disease? Investigations by magnetic spectroscopies.
    Fasano M; Bergamasco B; Lopiano L
    J Neural Transm (Vienna); 2006 Jun; 113(6):769-74. PubMed ID: 16755381
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Controversies about iron in parkinsonian and control substantia nigra.
    Gałazka-Friedman J; Friedman A
    Acta Neurobiol Exp (Wars); 1997; 57(3):217-25. PubMed ID: 9407708
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Isolation and 13C-NMR characterization of an insoluble proteinaceous fraction from substantia nigra of patients with Parkinson's disease.
    Aime S; Bergamasco B; Casu M; Digilio G; Fasano M; Giraudo S; Lopiano L
    Mov Disord; 2000 Sep; 15(5):977-81. PubMed ID: 11009208
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Quantifying iron deposition within the substantia nigra of Parkinson's disease by quantitative susceptibility mapping.
    An H; Zeng X; Niu T; Li G; Yang J; Zheng L; Zhou W; Liu H; Zhang M; Huang D; Li J
    J Neurol Sci; 2018 Mar; 386():46-52. PubMed ID: 29406966
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Iron accumulation in Parkinson's disease.
    Mochizuki H; Yasuda T
    J Neural Transm (Vienna); 2012 Dec; 119(12):1511-4. PubMed ID: 23070727
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Neuromelanin and iron in human locus coeruleus and substantia nigra during aging: consequences for neuronal vulnerability.
    Zucca FA; Bellei C; Giannelli S; Terreni MR; Gallorini M; Rizzio E; Pezzoli G; Albertini A; Zecca L
    J Neural Transm (Vienna); 2006 Jun; 113(6):757-67. PubMed ID: 16755380
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Neuromelanin in Parkinson's Disease: from Fenton Reaction to Calcium Signaling.
    Knörle R
    Neurotox Res; 2018 Feb; 33(2):515-522. PubMed ID: 28879408
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Converging roles of ion channels, calcium, metabolic stress, and activity pattern of Substantia nigra dopaminergic neurons in health and Parkinson's disease.
    Duda J; Pötschke C; Liss B
    J Neurochem; 2016 Oct; 139 Suppl 1(Suppl Suppl 1):156-178. PubMed ID: 26865375
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.